Stockscreener 앱 받기
2.15
7.73%
-0.18
시간 외 거래:
2.17
0.02
+0.93%
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 42.6% in October - MarketBeat
3 Promising Penny Stocks With Market Caps Over $20M - simplywall.st
How does Acrivon Therapeutics Inc (ACRV) change from a tortoise to a hare? - setenews.com
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsInflation Watch & Target Return Focused Picks - newser.com
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsRecession Risk & Precise Buy Zone Tips - newser.com
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Is Acrivon Therapeutics Inc. stock a contrarian buyIPO Watch & Short-Term Swing Trade Alerts - newser.com
Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Trading Recap & Consistent Growth Stock Picks - newser.com
What high frequency data says about Acrivon Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com
Custom strategy builders for tracking Acrivon Therapeutics Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
1.45%
0.86%
자본화:
|
볼륨(24시간):